Merck Q2 Earnings Preview: Analysts Expect 11% Decline in EPS and 1.4% Revenue Decrease
ByAinvest
Monday, Jul 28, 2025 7:57 pm ET1min read
MRK--
Despite these setbacks, Merck has a history of beating expectations. Over the last eight quarters, the company has consistently surpassed EPS and revenue estimates, with a 88% success rate for EPS and 100% for revenue [3]. However, recent market trends suggest a 4.9% swing for Merck shares, with an average daily move of 4.2% on earnings days [2].
Investors are also watching Merck's dividend yield, currently at 3.82% annually, or 81 cents per share per quarter. To generate $500 monthly, an investor would need to own approximately 1,852 shares, valued at around $156,883 [1]. For a more conservative goal of $100 monthly, 370 shares, valued at $31,343, would be sufficient [1].
Merck's stock has seen a 15.3% year-to-date decline, compared to a 1.9% decline for the S&P 500 healthcare index and a 5.2% gain for the Dow Industrials [2]. The company's shares last traded at $84.25, below the median price target of $100, with 27 analyst ratings, including six 'strong buy,' ten 'buy,' and eleven 'hold' ratings [2].
References:
[1] How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earnings. Benzinga. Retrieved from https://www.aol.com/earn-500-month-merck-stock-141223951.html
[2] Merck & Co MRK shares off ~0.6% on Mon ahead of Q2 financial report due before market open on Tues. Reuters. Retrieved from https://www.tradingview.com/news/reuters.com,2025:newsml_L6N3TP0SD:0-preview-merck-seen-reporting-q2-eps-drop-yr-yr-rev-increase/
[3] Merck Q2 Earnings Preview: What to Expect. Seeking Alpha. Retrieved from https://seekingalpha.com/news/4472805-merck-q2-earnings-preview-what-to-expect
Merck is set to report Q2 earnings on July 29th, with analysts expecting an 11% decline in EPS to $2.03 and a 1.4% decrease in revenue to $15.87B.
Merck & Co., Inc. (NYSE:MRK) is set to report its second-quarter earnings on Tuesday, July 29th, before the opening bell. Analysts expect an 11% decline in earnings per share (EPS) to $2.03, with a 1.4% decrease in revenue to $15.87 billion [3]. This comes as Merck navigates several challenges, including the failure of its Reblozyl anemia therapy in a Phase 3 trial for myelofibrosis and the start of late-stage clinical trials for its oral drug, MK-8527, aimed at preventing HIV [3].Despite these setbacks, Merck has a history of beating expectations. Over the last eight quarters, the company has consistently surpassed EPS and revenue estimates, with a 88% success rate for EPS and 100% for revenue [3]. However, recent market trends suggest a 4.9% swing for Merck shares, with an average daily move of 4.2% on earnings days [2].
Investors are also watching Merck's dividend yield, currently at 3.82% annually, or 81 cents per share per quarter. To generate $500 monthly, an investor would need to own approximately 1,852 shares, valued at around $156,883 [1]. For a more conservative goal of $100 monthly, 370 shares, valued at $31,343, would be sufficient [1].
Merck's stock has seen a 15.3% year-to-date decline, compared to a 1.9% decline for the S&P 500 healthcare index and a 5.2% gain for the Dow Industrials [2]. The company's shares last traded at $84.25, below the median price target of $100, with 27 analyst ratings, including six 'strong buy,' ten 'buy,' and eleven 'hold' ratings [2].
References:
[1] How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earnings. Benzinga. Retrieved from https://www.aol.com/earn-500-month-merck-stock-141223951.html
[2] Merck & Co MRK shares off ~0.6% on Mon ahead of Q2 financial report due before market open on Tues. Reuters. Retrieved from https://www.tradingview.com/news/reuters.com,2025:newsml_L6N3TP0SD:0-preview-merck-seen-reporting-q2-eps-drop-yr-yr-rev-increase/
[3] Merck Q2 Earnings Preview: What to Expect. Seeking Alpha. Retrieved from https://seekingalpha.com/news/4472805-merck-q2-earnings-preview-what-to-expect
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet